Obermatt
See Similar Stocks →

Flags

Financial distress

Gene One Life Science

KSC:011000 · KR7011000007
BiotechnologyX-Small

360

28
Medium confidence — indicative
Profit price56
Owner Earnings Yield1
Dividend Yield1
Price/Sales26
Price/Book52
Return on Capital66
Cash Return on Capital76
Return on Equity45
Profit margins25
Accruals51
Owner Earnings Margin59
Sales growth1
Profit growth24
Reinvestment92
Price momentum8
Debt load28
Refinancing4
Debt Payback1
Liquidity20
Analyst ratings—
Expectations trend—
Market mood49
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Gene One Life Science doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea
IndustryBiotechnology
SizeX-Small
TypePublic Company
ExchangeKOSE
Websitegenels.com
ISINKR7011000007
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
ImmunologyRheumatologyInflammationInfectious DiseasesVaccinesOncologyHepatologyBiopharma

Description

Analysis

Middle-of-the-road

GeneOne Life Science, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is mixed; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
1
2026

All-time high

4

Mar 2026

All-time low

1

Jun 2026

Average rank

3

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
26
—
—
—
Price/Earnings
—
—
—
—
Price/Book
52
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
31
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Gene One Life Science with its peers
Belite Bio
NAQ:BLTE
49
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Pharmicell
KSC:005690
35
CountrySouth Korea
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Towa Pharmaceutical
TYO:4553
50
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
WuXi Biologics (Cayman)
HKG:2269
87
CountryHong Kong SAR China
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Mayne Pharma
ASX:MYX
55
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Zai Lab
HKG:9688
32
CountryChina
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →